In Replay: Pneumocystis Pneumonia Following Rituximab

Routine pneumocystis pneumonia prophylaxis in patients treated with rituximab?

journal.publications.chestnet.org Figure 1. Proposed relationship among pulmonary infl ammation, systemic infl ammation, and COPDrelated comorbidities. *Statins have been shown to attenuate both pulmonary and systemic infl ammation through their effects on the innate immune response and NF k B/STAT3-mediated infl ammatory pathways. CRP 5 C-reactive protein; ETS 5 environmental tobacco smoke; M ...

Pneumocystis pneumonia.

Pneumocystis is an opportunistic fungus that is a major cause of morbidity and mortality in immunocompromised hosts. Despite a decline in incidence with the advent of highly active antiretroviral therapy (HAART), Pneumocystis remains the most common opportunistic infection in patients with the acquired immunodeficiency syndrome (AIDS) and is an increasing cause of disease in patients with other...

Lobar pentamidine levels and Pneumocystis carinii pneumonia following aerosolized pentamidine.

Recent studies have suggested that failure of pentamidine prophylaxis against Pneumocystis carinii pneumonia (PCP) may be due to reduced deposition of pentamidine in the upper lobes. In this study, we performed bronchoalveolar lavage from the apical segment of the upper lobe and the middle lobe in 51 HIV-positive patients, all of whom were receiving prophylaxis with aerosolized pentamidine, who...

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for...

Pneumocystis jiroveci pneumonia prophylaxis is a challenge in granulomatosis with polyangiitis patients treated with rituximab